Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 13, Art. 29 (pp. 359-371)    |    2012       

»

Reactive thrombocytosis

Koloskov A.V. 1,2, Saparkina M.B. 2, Philippova O.I. 1, Stolitsa A.A. 2

1City Hospital № 26, St.Petersburg, Russia
2Almazov federal heart, blood and endocrinology centre
Federal specialized perinatal center, St.Petersburg, Russia

Brief summary

Thrombocytosis is usually unexpected laboratory findings in the analysis of peripheral blood. The most common reason for the increase in platelet count in peripheral blood is a reactive or secondary process. The share of primary thrombocytosis caused by clonal proliferation in the bone marrow, accounts for about 10% of cases. Reactive (secondary) thrombocytosis observed in situations that can cause acute and transient increase in the number of platelets (trauma, major surgery, severe bleeding) or a more sustained thrombocytosis (iron deficiency, chronic infection, chronic inflammatory disease, neoplasia). This review presents the results of studies demonstrating the role of IL-6 in the development of thrombocytosis in patients with infectious and inflammatory diseases, and solid tumors. In patients with iron deficiency anemia the causes of thrombocytosis may be: 1) increased rate of influx of precursor cells into the megakaryocyte compartment with an increased rate of efflux; 2) shortening of megakaryocyte maturation; 3) stem-cell shunt due to inhibition of erythropoiesis, resulting in increased production of other pluripotent cells (hemostatic compensatory mechanism); 4) stimulator effect of transferrin on megakaryopoiesis; and 5) inhibition of iron on megakaryocyte maturation. Mechanisms of reactive thrombocytosis in patients with iron deficiency anemia are unclear.


Key words

thrombocytosis, megakaryocytopoiesis, thrombocytopoiesis, thrombopoietin, interleukin - 6

Reference list

1. Dame S., Sutor A.H. Primary and secondary thrombocytosis in childhood // Br. J. Haemol. - 2005. - Vol. 129. - P. 165 – 177.


2. Schafer A.I. Thrombocytosis // N. Engl. J. Med. – 2004. – Vol. 350. – P. 1211-1219.


3. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense // Blood. – 2005. – Vol. 105. – P. 4187-4190.


4. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis // Blood. – 2008. – Vol. 111. – P. 981-986.


5. Kaushansky K. The molecular mechanisms that control thrombopoiesis // J. Clin. Invest. – 2005. – Vol. 115. – P. 3339 - 3347.


6. Kuter D.J., Rosenberg R.D. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit // Blood. – 1995. – Vol. 85. – P. 2720 - 2730.


7. McCarty J.M., Sprugel K.H., Fox N.E. et al. Murine thrombopoietin mRNA levels are modulated by platelet count // Blood. – 1995. – Vol. 86. – P. 3668 - 3675.


8. Sungaran R., Markovic B., Chong B.H. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization // Blood. – 1997. – Vol. 89. – P. 101 - 107.


9. Guerriero A., Worford L., Holland H.K. et al. Thrombopoietin is synthesized by bone marrow stromal cells // Blood. – 1997. - Vol. 90. – P. 3444 - 3455.


10. Solanilla A., Dechanet J., Andaloussi A., et al. CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells // Blood. – 2000. – Vol. 95. – P. 3758 - 3764.


11. Sungaran R., Chisholm O.T., Markovic B. The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells // Blood. – 2000. – Vol. 95. – P. 3094 - 3101.


12. Ruggeri M., Tosetto A., Frezzato M., Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis // Ann. Intern. Med. – 2003. – Vol. 139. – P. 470 - 475.


13. Vannucchi A., Barbui T. Thrombocytosis and thrombosis // Hematology Am. Soc. Hematol. Educ. Program. – 2007. – P. 363 - 370.


14. Kaser A., Brandacher G., Steurer W. et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis // Blood. – 2001. – Vol. 98. – P. 2720 – 2725.


15. Wiwanitkit V. Extreme thrombocytosis: what are the etiologies? // Clin. Appl. Thromb. Hemost . – 2006. – Vol. 12. – P. 85 – 87.


16. Nijsten M., ten Duis H-J, Zijlstra J.G., et al. Blunted rise in platelet count in critically ill patients is associated with worse outcome // Crit. Care. Med. – 2000. – Vol. 28. – P. 3843 – 3846.


17. Akca S., Haji-Michael P., de Mendonca A. et al. Time course of platelet counts in critically ill patients // Crit. Care. Med. – 2002. – Vol. 30. – P. 753 – 756.


18. Gurung A.M., Carr B., Smith I. Thrombocytosis in intensive care // Br. J. Anaesth. – 2001. – Vol. 87. – P. 926 – 928.


19. Buss D.H., Cashell A.W., O’Connor M.L., Richards F. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases // Am. J. Med. – 1994. – Vol. 96. – P. 247 – 253.


20. Griesshammer M., Bangerter M., Sauer T. et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count // J. Int. Med. – 1999. – Vol. 245. – P. 295 – 300.


21. Valade N., Decailliot F., Rebufat Y. et al. Thrombocytosis after trauma: incidence, aetiology, and clinical significance // Br. J. Anaesth. – 2005. – Vol. 94. – P. 18 – 23.


22. Collins C.E., Rampton D.S. Review article: platelets in inflammatory bowel disease - pathogenetic role and therapeutic implications // Aliment. Pharmacol. Ther. – 1997. – Vol. 11. – P. 237 – 247.


23. Ertenli I., Kiraz S., Oztürk M.A. et al. Pathologic thrombopoiesis of rheumatoid arthritis // Rheumatol. Int. – 2003. – Vol. 23. – P. 49 – 60.


24. Unsal E., Aksaray S., Köksal D., Sipit T. Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis // Postgrad. Med. J. – 2005. – Vol. 81. – P. 604 – 607.


25. Klinger M.H., Jelkmann W. Role of blood platelets in infection and inflammation // J. Interferon Cytokine Res. – 2002. – Vol. 22. – P. 913 – 922.


26. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine // Adv. Immunol. – 1993. – Vol. 54. – P. 1 – 78.


27. Tilg H., Trehu E., Atkins M.B. et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 // Blood. – 1994. – Vol. 83. – P. 113 – 118.


28. Jordan M., Otterness I.G., Ng R. et al. Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist // J. Immunol. – 1995. – Vol. 154. – P. 4081 – 4090.


29. Kopf M., Baumann H., Freer G. et al. Impaired immune and acute-phase responses in interleukin-6 - deficient mice // Nature. - 1994. – Vol. 368. – P. 339 – 342.


30. Krishnan V., Araneda M., Hall K. Reactive and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins // South. Med. J. – 2007. – Vol. 144. – P. 417 – 420.


31. Stone R.L., Nick A.M., McNeish I.A. et al. Paraneoplastic thrombocytosis in ovarian cancer // N. Engl. J. Med. – 2012. – Vol. 366. – P. 610 – 618.


32. Akl E.A., van Doormaal F.F., Barba M. et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation // Cochrane Database Syst. Rev. – 2007; - 3:CD006652


33. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer // JAMA. – 2009; - Vol. 302. – P. 649 – 658.


34. Rothwell P.M., Wilson M., Eiwin C.E. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of randomized trials // Lancet. – 2010. – Vol. 376. – P. 1741 – 1750.


35. Kazuo D. Thrombocytosis in iron deficiency anemia // Intern. Med. – 2005. – Vol.44. – P. 1025 – 1026.


36. Kadikoylu G., Yavasoglu I., Bolaman Z., Senturk T. Platelet parameters in women with iron deficiency anemia // J. Natl.Med. Assoc. – 2006. – Vol.98. – P. 398 – 402.


37. Akan H., Guven N., Aydogdu I. et al. // Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis // Acta Haematol. – 2000. – Vol. 103. – P. 152-156.


38. Bilic E., Bilic E Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia // J. Pediatr. Hematol. Oncol. – 2003. – Vol. 25. – P. 919 – 920.


39. Racke F. EPO and TPO sequences do not explain thrombocytosis in iron deficiency anemia // J. Pediatr. Hematol. Oncol. – 2003. – Vol. 25. – P. 920.


40. Bal ik O.S., Öztürk M., Dağli M. et al. Increased erythropoietin ҫ levels in reactive thrombocytosis // Haematologia. – 2002. – Vol.32. – P. 59 – 65.


41. Beguin Y. Erythropoietin and platelet production // Haematologica – 1999. – V.84. – P.541 – 547.


42. Loo M., Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by adequacy of iron supply // Blood. – 1999. - Vol. 93. – P. 3286 – 3293.


43. Kellar K.L., Bridges N.B., Monroe M.C. et al. Maintenance of normal platelets mass in anemic Belgrade rats and their response to iron // Exp. Hematol. – 1990. – Vol. 18. – P. 979 – 984.